Patents Assigned to Wyeth LLC
  • Publication number: 20190314365
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 17, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10406220
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 10, 2019
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Patent number: 10376505
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 13, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10370424
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 6, 2019
    Assignee: Wyeth, LLC.
    Inventors: John Wozney, Howard Seeherman, Christopher Todd Brown
  • Patent number: 10357449
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 23, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Publication number: 20190209688
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 11, 2019
    Applicant: Wyeth LLC
    Inventors: Amanda R. Alley, William A. Bubnis, Stephanie Shield
  • Patent number: 10343989
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 9, 2019
    Assignee: WYETH LLC
    Inventors: Justin Keith Moran, Jianxin Gu
  • Patent number: 10307485
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 4, 2019
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Patent number: 10307417
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 4, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10301663
    Abstract: Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions for use in the methods of the present invention, are provided.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: May 28, 2019
    Assignee: Wyeth, LLC
    Inventors: Wei-Qiang Willie Sun, Earl Joseph Pursell
  • Patent number: 10292966
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 21, 2019
    Assignee: Wyeth LLC
    Inventors: Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
  • Publication number: 20190117646
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Publication number: 20190117645
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10238640
    Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 26, 2019
    Assignee: Wyeth LLC
    Inventors: Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Alley
  • Patent number: 10196433
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 5, 2019
    Assignee: Wyeth LLC
    Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
  • Patent number: 10111868
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 30, 2018
    Assignee: WYETH LLC
    Inventor: Charles Michael Zacharchuk
  • Patent number: 10035788
    Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 31, 2018
    Assignee: WYETH LLC
    Inventors: Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
  • Publication number: 20180162937
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Applicant: WYETH LLC
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
  • Patent number: 9988662
    Abstract: The present disclosure provides a method of reducing protein misfolding and aggregation in the cell culture by growing the cell culture at a reduced temperature and/or reduced pH. As a result, the quality of the protein produced in the cell culture is greatly improved. Thus, the present disclosure facilitates improvements in the efficacy of therapeutic proteins produced in cell culture.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: June 5, 2018
    Assignee: Wyeth LLC
    Inventors: Jose Manuel Gomes, Gregory Walter Hiller
  • Patent number: 9981035
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 29, 2018
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso